Biomarker · Gene alteration

BRCA2 mutation

Pathogenic germline or somatic BRCA2 variants detected by sequencing of blood or tumor; used as a predictive marker for PARP inhibitors and as a hereditary cancer-risk marker.

CI-BIO-00000033BRCA2 graph →NCIt C19636

Also calledBRCA2-mutated · gBRCA2 · germline BRCA2 · somatic BRCA2

Derived

Associated cancers (15)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Ovarian Neoplasm	16	15	1	—	3 / 7 / 6 / 0 / 0
Malignant Pancreatic Neoplasm	6	6	—	—	0 / 4 / 1 / 1 / 0
Ovarian Carcinoma	4	3	1	—	1 / 3 / 0 / 0 / 0
Malignant Breast Neoplasm	3	3	—	—	0 / 2 / 0 / 1 / 0
Malignant Prostate Neoplasm

Derived

Drugs with predictive evidence (15)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
OlaparibSmall Molecule	21	21	—	A	20 / 0	Breast Carcinoma, Castration-Resistant Prostate Carcinoma, Glioblastoma, Lung Carcinoma +10
RucaparibSmall Molecule	11	11	—	A

Curated evidence

Predictive evidence items (44)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–44 of 44 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRCA1 Mutation + BRCA2 MutationBRCA2 BRCA1

Regulatory

Approvals mentioning the linked drugs (223)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

BRCA2 Mutation19
Olaparib	Castration-Resistant Prostate Carcinoma	Predictive	A	Supports Sensitivity Response	5	accepted	EID8842 In phase 3 trial of 387 patients comparing olaparib and new hormonal agent (enzalutamide or abiraterone) therapy for patients with metastatic castration-resistant prostate cancer harboring homologous … (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	4	accepted	EID5831 Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2–negative metastatic breast cancer. 205 patients we… (full text at CIViC) PMID 28792849 · 2017 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Predictive	B	Supports Sensitivity Response	4	accepted	EID1371 In this phase 1 trial 60 patients with advanced solid tumors (ovarian, breast, colorectal, melanoma, sarcoma, prostate) were treated with PARP inhibitor olaparib. Durable antitumor activity was only o… (full text at CIViC) PMID 19553641 · Fong et al., 2009 · Open in CIViC	civic
〃	Malignant Ovarian Neoplasm	Predictive	A	Supports Sensitivity Response	5	accepted	EID7276 In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were rando… (full text at CIViC) PMID 30345884 · Moore et al., 2018 · Open in CIViC	civic
〃	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID1773 In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations. Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective r… (full text at CIViC) PMID 21862407 · Gelmon et al., 2011 · Open in CIViC	civic
Cediranib + OlaparibCombination	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID1678 46 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy. Median PFS was increased in combination therapy (… (full text at CIViC) PMID 25218906 · Liu et al., 2014 · Open in CIViC	civic
Rucaparib	Malignant Ovarian Neoplasm	Predictive	A	Supports Sensitivity Response	5	accepted	EID11137 Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC	civic
〃	Malignant Ovarian Neoplasm	Predictive	A	Supports Sensitivity Response	5	accepted	EID11139 Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC	civic
〃	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	2	accepted	EID2868 A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC	civic
〃	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID6343 A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC	civic
Iniparib	Malignant Pancreatic Neoplasm	Predictive	C	Supports Sensitivity Response	3	accepted	EID5936 Patient with germline BRCA2 mutation underwent resection of pancreatic cancer. Around three years later, tumor recurrence was detected by MRI and PET-CT confirmed it. She was treated with gemcitabine … (full text at CIViC) PMID 21508395 · Fogelman et al., 2011 · Open in CIViC	civic
Olaparib	Malignant Pancreatic Neoplasm	Predictive	B	Supports Sensitivity Response	4	accepted	EID5913 Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation. In total of patients with BRCA1/2 mutation , all but … (full text at CIViC) PMID 25366685 · Kaufman et al., 2015 · Open in CIViC	civic
Platinum Compound	Malignant Pancreatic Neoplasm	Predictive	B	Supports Sensitivity Response	4	accepted	EID5916 Patients with BRCA1/2 associated pancreatic adenocarcinoma were evaluated retrospectively. In patients with stage 3 and 4, the median overall survival (mOS) was 22 months for the platinum exposed (n=2… (full text at CIViC) PMID 25072261 · Golan et al., 2014 · Open in CIViC	civic
Veliparib	Malignant Pancreatic Neoplasm	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID5935 Veliparib 400mg bid was administered to patients with germline BRCA1/2 mutated pancreatic cancer. Sixteen pts was enrolled. All except two pts (12.5%) had previously been treated with platinum therapy… (full text at CIViC) PMID 29223478 · Lowery et al., 2018 · Open in CIViC	civic
Cisplatin + Gemcitabine + VeliparibCombination	Malignant Pancreatic Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID5933 In Phase I study for pancreatic cancer patients GEM 600 mg/m2 + CDDP 25 mg/m2 + Veliparib 20 - 80 mg twice daily showed response rate of 77.8% (7/9) and mOS of 23.3 months in germline BRCA mutation-p… (full text at CIViC) PMID 29338080 · O'Reilly et al., 2018 · Open in CIViC	civic
Platinum Compound	Ovarian Carcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID1530 In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0… (full text at CIViC) PMID 24240112 · Pennington et al., 2014 · Open in CIViC	civic
〃	Ovarian Carcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID1532 In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.… (full text at CIViC) PMID 24240112 · Pennington et al., 2014 · Open in CIViC	civic
Carboplatin + CisplatinSubstitutes	Triple-Negative Breast CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID1685 In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.0… (full text at CIViC) PMID 25847936 · Isakoff et al., 2015 · Open in CIViC	civic
Olaparib	Triple-Negative Breast CarcinomaALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID1776 In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative. Regardless of BRCA status, none showed objective response when treated with olaparib. PMID 21862407 · Gelmon et al., 2011 · Open in CIViC	civic

BRCA2 Loss-of-function10
Pidnarulex + QuarfloxinSubstitutes	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	4	accepted	EID1925 The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenog… (full text at CIViC) PMID 28211448 · Xu et al., 2017 · Open in CIViC	civic
Talazoparib	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	4	accepted	EID4839 In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment.… (full text at CIViC) PMID 28242752 · de Bono et al., 2017 · Open in CIViC	civic
Olaparib	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	4	accepted	EID212 The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA2 mutation positive women with high grade serous or undi… (full text at CIViC) PMID 23346317 · Goff, 2013 · Open in CIViC	civic
Talazoparib	Malignant Ovarian Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID4875 In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment.… (full text at CIViC) PMID 28242752 · de Bono et al., 2017 · Open in CIViC	civic
Mitomycin	Malignant Pancreatic Neoplasm	Predictive	D	Supports Sensitivity Response	2	accepted	EID1308 In pancreatic cell lines PL11 (FANCC-deficient) and CAPAN1 (BRCA2-mutated), sensitivity to DNA cross-linking agents was observed compared to FANCC/BRCA2 wildtype cell lines (Su86.86, CFPAC, AsPc1, and… (full text at CIViC) PMID 16243825 · van der Heijden et al., 2005 · Open in CIViC	civic
Olaparib	Malignant Prostate Neoplasm	Predictive	B	Supports Sensitivity Response	4	accepted	EID650 In a phase 2 trial of patients with metastatic, castration-resistant prostate cancer, treated with olaparib tablets at a dose of 400 mg twice a day, all 7 patients harbouring BRCA2 loss of function al… (full text at CIViC) PMID 26510020 · Mateo et al., 2015 · Open in CIViC	civic
〃	Pancreatic Adenocarcinoma	Predictive	A	Supports Sensitivity Response	5	accepted	EID7385 In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to ma… (full text at CIViC) PMID 31157963 · Golan et al., 2019 · Open in CIViC	civic
〃	Triple-Negative Breast CarcinomaALIAS	Predictive	A	Supports Sensitivity Response	5	accepted	EID11217 Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1… (full text at CIViC) PMID 34081848 · Tutt et al., 2021 · Open in CIViC	civic
〃	HER2 Negative Breast CancerUNRESOLVED	Predictive	A	Supports Sensitivity Response	5	accepted	EID11202 Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1… (full text at CIViC) PMID 34081848 · Tutt et al., 2021 · Open in CIViC	civic
〃	HER2 Negative Breast CancerUNRESOLVED	Predictive	B	Supports Sensitivity Response	3	accepted	EID5816 302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had signi… (full text at CIViC) PMID 28578601 · Robson et al., 2017 · Open in CIViC	civic

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE INJECTION (DIN 02565641) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE INJECTION (DIN 02555468) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 29, 2026	—	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE INJECTION (DIN 02455382) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION, USP (DIN 02437171) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 13, 2022	—	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION, USP (DIN 02437163) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jul 13, 2022	—	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as ACT GEMCITABINE (DIN 02436205) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Apr 27, 2020	—	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as ACT GEMCITABINE (DIN 02436191) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Apr 27, 2020	—	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02412101) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION USP (DIN 02409933) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION USP (DIN 02409925) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as AJ-GEMCITABINE (DIN 02409062) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Nov 3, 2015	—	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as AJ-GEMCITABINE (DIN 02409054) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Nov 3, 2015	—	health-canada-dpd
Gemcitabine	CA Health Canada	—	Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02402858) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Jan 12, 2022	—	health-canada-dpd
Mitomycin	CA Health Canada	—	Marketed in Canada as MITOMYCIN FOR INJECTION, USP (DIN 02531941) under ATC L01DC03 MITOMYCIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 27, 2023	health-canada-dpd
Mitomycin	CA Health Canada	—	Marketed in Canada as MITOMYCIN FOR INJECTION USP (DIN 02464691) under ATC L01DC03 MITOMYCIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 30, 2018	health-canada-dpd
Mitomycin	CA Health Canada	—	Marketed in Canada as MITOMYCIN FOR INJECTION USP (DIN 02237745) under ATC L01DC03 MITOMYCIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Feb 28, 2020	Jul 15, 1998	health-canada-dpd
Mitomycin	CA Health Canada	—	Marketed in Canada as MITOMYCIN FOR INJECTION USP (DIN 02230729) under ATC L01DC03 MITOMYCIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Feb 28, 2020	Mar 12, 1998	health-canada-dpd
Mitomycin	CA Health Canada	—	Marketed in Canada as MITOMYCIN FOR INJECTION (DIN 02230450) under ATC L01DC03 MITOMYCIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Feb 10, 2017	Oct 22, 1997	health-canada-dpd
Mitomycin	CA Health Canada	—	Marketed in Canada as MITOMYCIN FOR INJECTION (DIN 02230451) under ATC L01DC03 MITOMYCIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 22, 1997	health-canada-dpd
Mitomycin	CA Health Canada	—	Marketed in Canada as MUTAMYCIN INJ 20MG/VIAL (DIN 00587710) under ATC L01DC03 MITOMYCIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 29, 2006	Dec 31, 1984	health-canada-dpd
Mitomycin	CA Health Canada	—	Marketed in Canada as MUTAMYCIN INJ 5MG/VIAL (DIN 00381799) under ATC L01DC03 MITOMYCIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 29, 2006	Dec 31, 1977	health-canada-dpd
Mitomycin	CA Health Canada	—	Marketed in Canada as MITOMYCIN FOR INJECTION (DIN 02557762) under ATC L01DC03 MITOMYCIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Niraparib	CA Health Canada	—	Marketed in Canada as ZEJULA (DIN 02530031) under ATC L01XK02 NIRAPARIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 13, 2023	health-canada-dpd
Niraparib	CA Health Canada	—	Marketed in Canada as AKEEGA (DIN 02538555) under ATC L01XK52 NIRAPARIB AND ABIRATERONE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 14, 2023	health-canada-dpd
Niraparib	CA Health Canada	—	Marketed in Canada as AKEEGA (DIN 02538563) under ATC L01XK52 NIRAPARIB AND ABIRATERONE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 14, 2023	health-canada-dpd
Niraparib	CA Health Canada	—	Marketed in Canada as ZEJULA (DIN 02489783) under ATC L01XK02 NIRAPARIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Oct 26, 2024	Jan 9, 2020	health-canada-dpd
Olaparib	CA Health Canada	—	Marketed in Canada as LYNPARZA (DIN 02475219) under ATC L01XK01 OLAPARIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 23, 2018	health-canada-dpd
Olaparib	CA Health Canada	—	Marketed in Canada as LYNPARZA (DIN 02475200) under ATC L01XK01 OLAPARIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 23, 2018	health-canada-dpd
Olaparib	CA Health Canada	—	Marketed in Canada as LYNPARZA (DIN 02454408) under ATC L01XK01 OLAPARIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jan 11, 2021	May 16, 2016	health-canada-dpd
Talazoparib	CA Health Canada	—	Marketed in Canada as TALZENNA (DIN 02492032) under ATC L01XK04 TALAZOPARIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 16, 2025	health-canada-dpd
Talazoparib	CA Health Canada	—	Marketed in Canada as TALZENNA (DIN 02555050) under ATC L01XK04 TALAZOPARIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 16, 2025	health-canada-dpd
Talazoparib	CA Health Canada	—	Marketed in Canada as TALZENNA (DIN 02555069) under ATC L01XK04 TALAZOPARIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Talazoparib	CA Health Canada	—	Marketed in Canada as TALZENNA (DIN 02555077) under ATC L01XK04 TALAZOPARIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Talazoparib	CA Health Canada	—	Marketed in Canada as TALZENNA (DIN 02492040) under ATC L01XK04 TALAZOPARIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as JAMP TEMOZOLOMIDE (DIN 02516802) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 5, 2022	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as JAMP TEMOZOLOMIDE (DIN 02516799) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 27, 2022	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as JAMP TEMOZOLOMIDE (DIN 02516845) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 26, 2022	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as JAMP TEMOZOLOMIDE (DIN 02516829) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 26, 2022	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as JAMP TEMOZOLOMIDE (DIN 02516810) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 25, 2022	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as ACH-TEMOZOLOMIDE (DIN 02438119) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 13, 2016	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as TEVA-TEMOZOLOMIDE (DIN 02441160) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 8, 2015	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as TARO-TEMOZOLOMIDE (DIN 02443473) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 23, 2015	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as TARO-TEMOZOLOMIDE (DIN 02443554) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 23, 2015	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as TARO-TEMOZOLOMIDE (DIN 02443481) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 23, 2015	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as TARO-TEMOZOLOMIDE (DIN 02443511) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 23, 2015	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as TARO-TEMOZOLOMIDE (DIN 02443538) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 23, 2015	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as TEVA-TEMOZOLOMIDE (DIN 02395274) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Nov 7, 2012	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as TEVA-TEMOZOLOMIDE (DIN 02395282) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Nov 7, 2012	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as TEVA-TEMOZOLOMIDE (DIN 02395312) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Nov 7, 2012	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as TEVA-TEMOZOLOMIDE (DIN 02395290) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Nov 7, 2012	health-canada-dpd

Associated cancers (15)

Drugs with predictive evidence (15)

Predictive evidence items (44)

Approvals mentioning the linked drugs (223)

Active trials (554)

Linked publications (33)